Shire’s haemophilia treatment recommended for EU marketing authorisation

MaxCyte and NIH to develop therapies for sickle cell disease
Credit: Romaset

CHMP has recommended EU marketing authorisation for Adynovi, Shire’s treatment for adults and adolescents with Haemophilia A.

Adynovi is an extended half-life recombinant Factor VIII treatment, for adults and adolescents ages 12 and older living with haemophilia A for on-demand and prophylactic use.

If approved, it would offer twice-weekly prophylactic dosing as well as on-demand control of bleeding episodes.

The CHMP submission was based on outcomes from three Phase 3 clinical trials of patients with haemophilia A.

CHMP’s Positive Opinion will be reviewed by the European Commission, which has the authority to grant marketing authorization in the EU.